表 3.

ICIs对HER2突变的NSCLC的疗效

Efficacy of ICIs for HER2-mutated NSCLC

Study	Year	Mutation	Subtype	Treatment	ICI line	Total No.	ORR	DCR	mPFS (mon)	mOS (mon)
Dudnik, et al[10]	2018	HER2	HER2 mutation	PD-(L)1 mAb	2	7	14%	-	3.4	17.5
	2018	HER2	HER2 amplification	PD-(L)1 mAb	2	5	20%	-	6.3	10.4
Mazieres, et al[13]	2019	HER2	NA	94% PD-1 mAb	3	29	7%	33%	2.5	20.3
Guisier, et al[16]	2020	HER2	HER2 mutation	PD-(L)1 mAb	3	23	27%	50%	2.2	20.4
Lai, et al[21]	2018	HER2	HER2 mutation	ICIs	-	26	12%	42%	1.9	10.4